Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EPS (Basic) (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EPS (Basic) for 5 consecutive years, with -$3.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 77.1% year-over-year to -$3.0, compared with a TTM value of -$2.45 through Dec 2025, up 88.3%, and an annual FY2025 reading of -$2.45, up 88.3% over the prior year.
  • EPS (Basic) was -$3.0 for Q4 2025 at Aligos Therapeutics, up from -$3.04 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $5.12 in Q1 2025 and bottomed at -$22.87 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$3.15, with a median of -$0.82 recorded in 2021.
  • The sharpest move saw EPS (Basic) tumbled 4384.31% in 2023, then skyrocketed 288.37% in 2024.
  • Year by year, EPS (Basic) stood at -$0.91 in 2021, then skyrocketed by 43.96% to -$0.51 in 2022, then crashed by 4384.31% to -$22.87 in 2023, then skyrocketed by 42.72% to -$13.1 in 2024, then surged by 77.1% to -$3.0 in 2025.
  • Business Quant data shows EPS (Basic) for ALGS at -$3.0 in Q4 2025, -$3.04 in Q3 2025, and -$1.53 in Q2 2025.